Alliance for Pandemic Preparedness

June 29, 2020

Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects

Category:

Topic:

  • Two phase I studies evaluating the safety and pharmacokinetics of single escalating and multiple intravenous (IV) doses of remdesivir in healthy subjects found all adverse events were grade 1 or 2 in severity (mild to moderate, with only minimal, local, or non-invasive treatment needed) and that once daily dosing is appropriate. 

Humeniuk et al. (June 2020). Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects. Clinical and Translational Science. https://doi.org/10.1111/cts.12840